---
document_datetime: 2025-12-29 09:10:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/liprolog-0.html
document_name: liprolog-0.html
version: success
processing_time: 0.0427233
conversion_datetime: 2025-12-30 00:09:08.889488
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Liprolog

[RSS](/en/individual-human-medicine.xml/66203)

##### Withdrawn

This medicine's authorisation has been withdrawn

insulin lispro Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 7 May 1997, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Liprolog, which contains insulin lispro. The pharmaceutical company responsible for this medicinal product is Eli Lilly and Company Ltd.

On 7 December 2000, the Marketing Authorisation holder notified the European Commission about the Marketing Authorisation holder's decision to withdraw the Marketing Authorisation for Liprolog.

On 19 February 2001, the European Commission has adopted the decision withdrawing the Marketing Authorisation for the medicinal product for human use, Liprolog - insulin lispro EU 1/97/038/001-003. Pursuant to this decision the European Public Assesment Report for Liprolog has been removed from this website.

For information, it should be noted that at present there is still a Marketing Authorisation valid throughout the European Union for the medicinal product Humalog, which contains insulin lispro. The pharmaceutical company responsible for this medicinal product is Eli Lilly and Company Ltd.

Following a later application by the company, the European Commission [granted a marketing authorisation](/node/66998) for the medicine.

## Product information

19/02/2001

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Liprolog Active substance insulin lispro International non-proprietary name (INN) or common name insulin lispro Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AB04

### Pharmacotherapeutic group

- Drugs used in diabetes
- Insulins and analogues for injection, fast-acting

### Therapeutic indication

For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.

## Authorisation details

EMA product number EMEA/H/C/000143 Marketing authorisation holder

Eli Lilly and Company Limited

Kingsclere Road

Marketing authorisation issued 07/05/1997 Withdrawal of marketing authorisation 19/02/2001

**This page was last updated on** 01/08/2001

## Share this page

[Back to top](#main-content)